source
- FDA rejects Capricor's Duchenne cell therapy citing serious data integrity violationsThe Food and Drug Administration issued a second rejection of Capricor Therapeutics' cell therapy, deramiocel, aimed at treating Duchenne muscular dystrophy. The agency said the revised application…
- FDA rejects Capricor’s Duchenne cell therapy after trials show no benefitThe Food and Drug Administration announced that it is rejecting deramiocel, a cell therapy for Duchenne muscular dystrophy developed by Capricor Therapeutics. The treatment was aimed at teenage an…